Charles Yeh

Charles Yeh received his PhD from ETH Zurich in 2024 wherein he developed a novel high-sensitivity in situ/in vivo system (RaPID-seq) for monitoring homology search during DNA double-stranded break homology-directed repair (DSBR/HDR). A major theme of Charles’ research is furthering our understanding of basic genome biology and applying this knowledge in a translational context through a combination of cutting-edge next-generation sequencing (NGS) technologies and computational analysis. This research has not only included understanding how basic DNA repair mechanisms lead to different genome editing outcomes, but also how we can modulate these pathways to specifically enrich for desired outcomes.

Prior to his doctoral studies, Charles conducted research at the National Center for Advancing Translational Sciences (NCATS) at the US National Institutes of Health (NIH) as a member of the Therapeutics for Rare and Neglected Diseases (TRND) program. Therein, Charles developed and applied novel human stem cell-derived disease models and high-throughput screening technologies to identify potential therapeutics for rare lysosomal storage disorders, including Farber and Wolman diseases.